Tetryzoline
RESPIRATORY SYSTEM
Also known as: (+/-)-Tetrahydrozoline, dl-Tetrahydrozoline, ocuzolin, tetrahydrozeline HCl, tetrahydrozeline hydrochloride, tetrahydrozeline nitrate, tetrahydrozoline, tetrahydrozoline HCl, tetrahydrozoline hydrochloride, tetrahydrozoline nitrate, tetryzolin
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Tetryzoline is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1979. DrugCentral lists 4 molecular targets, including Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a, Adra2b|Adra2c|Adra2a and Adra1b|Adra1d|Adra1a. Recorded indications include Nasal congestion, Nasal discharge and Red eye.
- Approval status: ofp (first approved 1979 by the FDA).
- Molecular targets: Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a, Adra2b|Adra2c|Adra2a, Adra1b|Adra1d|Adra1a and ADRA2A|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B (4 listed in DrugCentral).
- Indications: Nasal congestion, Nasal discharge and Red eye.
- ATC code: R01AA06 (Sympathomimetics, plain).
- Molecular formula: C13H16N2; molecular weight 200.28 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- Nasal congestion
- Nasal discharge
- Red eye
Contraindications (3)
- Diabetes mellitus
- Disorder of cardiovascular system
- Hyperthyroidism
Mechanism & targets
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Adrenergic receptor alpha | Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a | unknown | Ki 7.96 |
| Adrenergic receptor alpha-2 | Adra2b|Adra2c|Adra2a | unknown | IC50 7.52 |
| Adrenergic receptor alpha-1 | Adra1b|Adra1d|Adra1a | unknown | IC50 5.80 |
| Adrenergic receptor alpha | ADRA2A|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B | agonist | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1979-11-30 | FDA | — | FOUGERA PHARMS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
R01AA06 | RESPIRATORY SYSTEM › NASAL PREPARATIONS › DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE › Sympathomimetics, plain |
R01AB03 | RESPIRATORY SYSTEM › NASAL PREPARATIONS › DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE › Sympathomimetics, combinations excl. corticosteroids |
S01GA02 | SENSORY ORGANS › OPHTHALMOLOGICALS › DECONGESTANTS AND ANTIALLERGICS › Sympathomimetics used as decongestants |
S01GA52 | SENSORY ORGANS › OPHTHALMOLOGICALS › DECONGESTANTS AND ANTIALLERGICS › Sympathomimetics used as decongestants |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Burns second degree | 329.6 |
| Catarrh | 328.9 |
| Steroid dependence | 308.8 |
| Hypopnoea | 296.8 |
| Parosmia | 284.4 |
| Gingival pain | 270.0 |
| Rhinitis | 244.5 |
| Alcohol poisoning | 244.4 |
| Cardiac murmur | 233.8 |
| Bronchiectasis | 222.5 |
| Impaired work ability | 220.2 |
| Nightmare | 203.4 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Tetryzoline is on its molecule page.
| Molecular formula | C13H16N2 |
|---|---|
| Molecular weight | 200.28 g/mol |
| CAS number | 84-22-0 |
| InChIKey | BYJAVTDNIXVSPW-UHFFFAOYSA-N |
| PubChem CID | 5419 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Tetryzoline used for?
DrugCentral lists the following indications for Tetryzoline: Nasal congestion, Nasal discharge and Red eye.
How does Tetryzoline work?
Its molecular targets in DrugCentral include Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a, Adra2b|Adra2c|Adra2a, Adra1b|Adra1d|Adra1a and ADRA2A|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B (agonist).
When was Tetryzoline first approved?
Tetryzoline was first approved by the FDA in 1979.
What is the chemical formula of Tetryzoline?
Tetryzoline has the molecular formula C13H16N2 and a molecular weight of 200.28 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 3591 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200413 — compound record and bioactivity
- PubChem CID 5419 — chemical identifiers
- DrugBank DB06764 — drug record
- FDA UNII 8P9X484T3F — substance identity
- DailyMed: FDA labels for Tetryzoline — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.